Cooper Companies

The Cooper Companies lowered its fiscal 2026 revenue and adjusted EPS guidance after weaker-than-expected contact lens demand weighed on CooperVision; Q3 revenue was $1.07 billion versus $1.10 billion expected while adjusted EPS of $1.15 beat estimates. Management cited U.S. channel inventory reductions that are expected to continue into Q4 and now forecasts CooperVision organic growth of 1%–2% for fiscal 2026 (Q4: -2% to 0%). The company completed a strategic review and will retain CooperSurgical, increased its share buyback authorization to $3 billion, and highlighted strong free cash flow and product investment as potential supports if demand normalizes. » More on finance.yahoo.com

Cooper Companies reported Q3 revenue of $1.07 billion, missing consensus, while adjusted EPS of $1.15 slightly beat. Management cut the Q4 outlook to $1.057–1.080 billion (organic growth 0–2%), primarily pressured by inventory destocking in CooperVision’s U.S. distribution channel. The board decided not to sell CooperSurgical after a strategic review, and analysts reacted with downgrades and significantly lower price targets. An increase in the buyback authorization to $3 billion and a record free cash flow of $273 million failed to offset the negative market response. » More on de.investing.com

Cooper Companies reported non-GAAP earnings per share of $1.15 for Q3 2026 (above the $1.12 consensus), while revenue of $1.07 billion missed the $1.1 billion forecast. The stock fell sharply in regular trading and declined further in after-hours trading as investors reacted with concern to weaker sales, accelerated inventory drawdown at CooperVision and a cautious near-term outlook. Positive highlights include a record free cash flow of $273 million and an increase of the share repurchase authorization by $1 billion, but management lowered the revenue outlook for CooperVision and expects Q4 revenue of $1.057–1.08 billion and adjusted EPS of $1.05–1.09. » More on de.investing.com

CooperCompanies has ended the strategic review and unanimously decided not to sell the CooperSurgical division, as the offers received were not in shareholders' best interests. The board cited favorable market and legal factors as reasons behind the low valuations. The share buyback program is increased from $2 billion to $3 billion; $445 million in repurchases have already been made since the fiscal year began. The company plans operational improvements, investments in CooperVision, and will open the global R&D center "The Vision Centre" on September 23, 2026. » More on de.investing.com

Cooper Companies will present results for the quarter ended July 31, 2026 on September 9, 2026. Fifteen analysts on average expect earnings per share of $1.12 (prior year $0.49) and revenue of about $1.10 billion (prior year $1.06 billion, +3.6%). For the fiscal year, sixteen analysts forecast on average $4.63 earnings per share (prior year $1.87) and revenue of about $4.31 billion (prior year $4.09 billion). » More on finanzen.net